A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
Clinical trial NCT03502707 · COMPLETED
Trial details
- NCT number
- NCT03502707
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-06
- Primary completion
- 2022-05-16
- Enrollment
- 669
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.